Evidence map›Paper›PMID 32876938›Full record

ArticleJournal of nephrology2021

Outbreak of chronic renal failure: will this be a delayed heritage of COVID-19?

Niloofar Khoshdel-Rad, Ensieh Zahmatkesh, Anastasia Shpichka, Peter Timashev, Massoud Vosough

Abstract readEditorial
In one paragraph

Article in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. An update to "novel therapeutic approaches for treatment of COVID-19".Journal of molecular medicine (Berlin, Germany) · 2021
    Article
  12. Article
  13. Review
  14. Non-respiratory presentations of COVID-19, a clinical review.The American journal of emergency medicine · 2020
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Niloofar Khoshdel-RadDepartment of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Ensieh ZahmatkeshDepartment of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Anastasia ShpichkaInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Peter TimashevInstitute for Regenerative Medicine, Sechenov University, Moscow, Russia. timashev.peter@gmail.com.
Massoud VosoughDepartment of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. masvos@royaninstitute.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19HumansKidney Failure, ChronicSARS-CoV-2Angiotensin-Converting Enzyme 2Acute kidney injuryChronic renal failureCoronavirusCOVID-19Renal damageSARS-CoV-2

Identifiers

PMID32876938
PMCPMC7464059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.